CHRO
Price
$1.41
Change
+$0.10 (+7.63%)
Updated
Apr 8, 01:28 PM (EDT)
Capitalization
7.9M
50 days until earnings call
KLRS
Price
$7.10
Change
+$0.50 (+7.58%)
Updated
Apr 8, 04:59 PM (EDT)
Capitalization
123.44M
23 days until earnings call
Ad is loading...

CHRO vs KLRS

Header iconCHRO vs KLRS Comparison
Open Charts CHRO vs KLRSBanner chart's image
Channel Therapeutics
Price$1.41
Change+$0.10 (+7.63%)
VolumeN/A
Capitalization7.9M
Kalaris Therapeutics
Price$7.10
Change+$0.50 (+7.58%)
Volume$100
Capitalization123.44M
CHRO vs KLRS Comparison Chart
Loading...
CHRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KLRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRO vs. KLRS commentary
Apr 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRO is a StrongBuy and KLRS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 09, 2025
Stock price -- (CHRO: $1.31 vs. KLRS: $6.60)
Brand notoriety: CHRO and KLRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRO: 14% vs. KLRS: 224%
Market capitalization -- CHRO: $7.9M vs. KLRS: $123.44M
CHRO [@Biotechnology] is valued at $7.9M. KLRS’s [@Biotechnology] market capitalization is $123.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $283.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRO’s FA Score shows that 0 FA rating(s) are green whileKLRS’s FA Score has 1 green FA rating(s).

  • CHRO’s FA Score: 0 green, 5 red.
  • KLRS’s FA Score: 1 green, 4 red.
According to our system of comparison, KLRS is a better buy in the long-term than CHRO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRO’s TA Score shows that 2 TA indicator(s) are bullish while KLRS’s TA Score has 3 bullish TA indicator(s).

  • CHRO’s TA Score: 2 bullish, 6 bearish.
  • KLRS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, KLRS is a better buy in the short-term than CHRO.

Price Growth

CHRO (@Biotechnology) experienced а -7.75% price change this week, while KLRS (@Biotechnology) price change was -17.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.88%. For the same industry, the average monthly price growth was -20.27%, and the average quarterly price growth was -19.68%.

Reported Earning Dates

CHRO is expected to report earnings on May 28, 2025.

KLRS is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-9.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KLRS($123M) has a higher market cap than CHRO($7.9M). KLRS YTD gains are higher at: 1471.429 vs. CHRO (104.368).
CHROKLRSCHRO / KLRS
Capitalization7.9M123M6%
EBITDA-9.23MN/A-
Gain YTD104.3681471.4297%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash1.26MN/A-
Total Debt2.29MN/A-
TECHNICAL ANALYSIS
Technical Analysis
CHROKLRS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
85%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 5 days ago
81%
View a ticker or compare two or three
Ad is loading...
CHRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KLRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSMRX13.43N/A
N/A
RBC SMID Cap Growth R6
DISCX20.34N/A
N/A
BNY Mellon International Stock Fund C
MRJAX10.32N/A
N/A
Morgan Stanley Multi-Asset Real Return A
FIJCX84.93N/A
N/A
Fidelity Advisor Consumer Staples Z
IWTTX11.35-0.21
-1.82%
Voya Global High Dividend Low Vol PortS2

CHRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRO has been loosely correlated with KLRS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRO jumps, then KLRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRO
1D Price
Change %
CHRO100%
-3.94%
KLRS - CHRO
41%
Loosely correlated
-6.78%
INO - CHRO
24%
Poorly correlated
+1.28%
ELEV - CHRO
24%
Poorly correlated
-1.76%
TBPH - CHRO
22%
Poorly correlated
-0.36%
NAYA - CHRO
21%
Poorly correlated
+14.56%
More

KLRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KLRS has been loosely correlated with CHRO. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if KLRS jumps, then CHRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KLRS
1D Price
Change %
KLRS100%
-6.78%
CHRO - KLRS
41%
Loosely correlated
-3.94%
SPRO - KLRS
21%
Poorly correlated
+3.06%
ASBP - KLRS
3%
Poorly correlated
-11.07%
RNTX - KLRS
3%
Poorly correlated
-3.53%
OSRH - KLRS
2%
Poorly correlated
-21.54%
More